NCT04953923 is a Phase 1 clinical trial of Cedazuridine in Healthy Volunteers, sponsored by Astex Pharmaceuticals, Inc..

Who is sponsoring NCT04953923?

NCT04953923 is sponsored by Astex Pharmaceuticals, Inc..

What drugs are being tested in NCT04953923?

Interventions in NCT04953923: Cedazuridine, Placebo, Moxifloxacin.

What condition does NCT04953923 study?

NCT04953923 studies Healthy Volunteers.

Is NCT04953923 still recruiting?

NCT04953923 is currently completed. Last updated 2 August 2024.

Last reviewed 2024-08-02 · How we verify

NCT04953923

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thorough QT Assessment of Cedazuridine in Healthy Subjects

Completed Phase 1 Last updated 2 August 2024

What this trial tests

Phase 1 trial testing Cedazuridine in Healthy Volunteers in 36 participants. Completed in 16 November 2021.

Timeline

1 July 2021

Primary endpoint
15 November 2021

16 November 2021

Quick facts

Lead sponsor	Astex Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	basic science
Enrollment	36
Start date	1 July 2021
Primary completion	15 November 2021
Estimated completion	16 November 2021
Sites	1 location across Netherlands

Drugs / interventions tested

Cedazuridine — full drug profile →
Placebo
Moxifloxacin (moxifloxacin) — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Astex Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to evaluate the effect of therapeutic and supratherapeutic oral doses of cedazuridine on cardiac repolarization, as detected by QTc in healthy subjects, in accordance with regulatory guidelines. Moxifloxacin will be used to validate the study. Study duration per participant is approximately 20 days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cedazuridine

Trials testing the same drug.

NCT05799079 — Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid · Phase 2 · terminated
NCT04985656 — A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes · Phase 2 · withdrawn
NCT04256317 — A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetocla · Phase 2, PHASE3 · recruiting
NCT03875287 — Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors · Phase 1 · active not recruiting

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Astex Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT05835011 — A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-R · Phase 2 · terminated
NCT04637009 — A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms · Phase 1 · terminated
NCT04466514 — A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029 · Phase 1 · completed
NCT04479800 — Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers · Phase 1 · completed
NCT04155580 — A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04953923 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Astex Pharmaceuticals, Inc.
Last refreshed: 2 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04953923.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing